ALK and non-small cell lung carcinoma: For example, molecularly-targeted drugs, such as epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) or anaplastic lymphoma kinase (ALK)-TKI, are effective in improving performance status (PS) or respiratory conditions in driver oncogenes positive non-small cell lung cancer (NSCLC) patients even with poor PS [6, 7], or respiratory condition [8].